What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cancer
Norihiro Nishimoto mainly focuses on Interleukin 6, Immunology, Internal medicine, Arthritis and Rheumatoid arthritis.
His research in Interleukin 6 intersects with topics in Cancer research and Pathology, Histology.
Norihiro Nishimoto combines topics linked to Castleman disease with his work on Immunology.
Norihiro Nishimoto combines subjects such as Gastroenterology, Placebo and Surgery with his study of Internal medicine.
His Arthritis research is multidisciplinary, incorporating perspectives in Autoimmune disease, Antibody and Disease.
Norihiro Nishimoto studies Rheumatoid arthritis, focusing on Tocilizumab in particular.
His most cited work include:
- Structure and function of a new STAT-induced STAT inhibitor (1185 citations)
- Pathogenic Significance of Interleukin-6 (IL-6/BSF-2) in Castleman's Disease (743 citations)
- Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: A multicenter, double‐blind, placebo‐controlled trial (706 citations)
What are the main themes of his work throughout his whole career to date?
Immunology, Internal medicine, Rheumatoid arthritis, Interleukin 6 and Tocilizumab are his primary areas of study.
The various areas that he examines in his Immunology study include Receptor and Disease.
His Internal medicine study incorporates themes from Gastroenterology, Endocrinology and Surgery.
The concepts of his Rheumatoid arthritis study are interwoven with issues in Abatacept, Arthritis, Immune system, Interleukin and Drug.
His studies examine the connections between Arthritis and genetics, as well as such issues in Randomized controlled trial, with regards to Placebo.
His Interleukin 6 research is multidisciplinary, incorporating elements of Castleman disease, Cancer research, Cell culture and Pathology.
He most often published in these fields:
- Immunology (50.00%)
- Internal medicine (45.05%)
- Rheumatoid arthritis (43.69%)
What were the highlights of his more recent work (between 2012-2020)?
- Internal medicine (45.05%)
- Rheumatoid arthritis (43.69%)
- Immunology (50.00%)
In recent papers he was focusing on the following fields of study:
Norihiro Nishimoto mainly investigates Internal medicine, Rheumatoid arthritis, Immunology, Tocilizumab and Abatacept.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Surgery.
His Rheumatoid arthritis research includes elements of Cohort study, Synovial fluid, Interleukin, Physical therapy and Antibody.
His work in the fields of Immunology, such as Interleukin 6, Immune system, Autoantibody and Bone marrow, intersects with other areas such as RANKL.
His work deals with themes such as Adverse effect, Serious infection, Drug and Arthritis, which intersect with Tocilizumab.
His work investigates the relationship between Abatacept and topics such as T cell that intersect with problems in Cytokine.
Between 2012 and 2020, his most popular works were:
- The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis (248 citations)
- Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study) (130 citations)
- Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions (95 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Cancer
His primary areas of investigation include Tocilizumab, Internal medicine, Rheumatoid arthritis, Immunology and Drug.
The Tocilizumab study combines topics in areas such as Antibody and Arthritis.
His research combines Gastroenterology and Internal medicine.
The Rheumatoid arthritis study which covers Rheumatology that intersects with Meta-analysis and Ankylosing spondylitis.
His Interleukin-6 receptor, Vaccination and Influenza vaccine study, which is part of a larger body of work in Immunology, is frequently linked to Pneumococcal polysaccharide vaccine and Pneumococcal vaccine, bridging the gap between disciplines.
His Adverse effect research is multidisciplinary, relying on both Young adult, Placebo, Surgery and Clinical endpoint.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
